2122. The Impact of HHV-6 DNAemia on hematopoietic cell transplant (HCT) recipients at high risk for CMV reactivation in the era of Letermovir

BACKGROUND: Letermovir (LTV) has reduced non-relapse mortality (NRM) in allogeneic hematopoietic cell transplant (allo-HCT) recipients by reducing the rate of clinically significant cytomegalovirus infections (CS-CMVi). The impact of LTV prophylaxis (PP) on other infections is unclear. We investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Srinivasan, Krithia, Spallone, Amy, Khawaja, Fareed, Sassine, Joseph, Aramburo, Oscar Morado, Febres-Aldana, Anthony J, Rondon, Gabriella, Ramdial, Jeremy, Shpall, Elizabeth, Ariza-Heredia, Ella, Chemaly, Roy F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752522/
http://dx.doi.org/10.1093/ofid/ofac492.1743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752522/
http://dx.doi.org/10.1093/ofid/ofac492.1743

Ejemplares similares